Charles Osborne
Director of Finance/CFO bei POLAREAN IMAGING PLC
Profil
Charles Fremont Osborne is currently the Chief Financial Officer & Director at Polarean Imaging Plc.
Previously, he held the position of Vice President-Finance at International Murex Technologies Corp.
From 2003 to 2015, he served as the Chief Financial Officer at SCYNEXIS, Inc. He also worked as the Chief Financial Officer at Nobex Corp.
In addition, he was the Chief Financial Officer & Secretary at Innocrin Pharmaceuticals, Inc. from 2015 to 2019.
Mr. Osborne obtained his undergraduate degree from The University of North Carolina at Charlotte in 1987.
Aktive Positionen von Charles Osborne
| Unternehmen | Position | Beginn |
|---|---|---|
| POLAREAN IMAGING PLC | Director of Finance/CFO | 29.04.2019 |
Ehemalige bekannte Positionen von Charles Osborne
| Unternehmen | Position | Ende |
|---|---|---|
Innocrin Pharmaceuticals, Inc.
 Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Director of Finance/CFO | 01.04.2019 |
| SCYNEXIS, INC. | Director of Finance/CFO | 30.06.2015 |
International Murex Technologies Corp.
 International Murex Technologies Corp. Medical SpecialtiesHealth Technology International Murex Technologies Corp. develops medical diagnostic products. It provides infectious disease screening services. The company is headquartered in Norcross, GA. | Director of Finance/CFO | - |
Nobex Corp.
 Nobex Corp. Pharmaceuticals: MajorHealth Technology Protein Delivery Inc. is drug delivery company. It specializes in proprietary polymer-based technology for the stabilization and oral delivery of proteins and peptides as well as the delivery of small molecules across the blood-brain barrier. The company's technology also enables the delivery of drugs into the brain to treat diseases of the central nervous system. Protein Delivery is located in Durham, NC | Director of Finance/CFO | - |
Ausbildung von Charles Osborne
| The University of North Carolina at Charlotte | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SCYNEXIS, INC. | Health Technology |
| POLAREAN IMAGING PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
International Murex Technologies Corp.
International Murex Technologies Corp. Medical SpecialtiesHealth Technology International Murex Technologies Corp. develops medical diagnostic products. It provides infectious disease screening services. The company is headquartered in Norcross, GA. | Health Technology |
Nobex Corp.
Nobex Corp. Pharmaceuticals: MajorHealth Technology Protein Delivery Inc. is drug delivery company. It specializes in proprietary polymer-based technology for the stabilization and oral delivery of proteins and peptides as well as the delivery of small molecules across the blood-brain barrier. The company's technology also enables the delivery of drugs into the brain to treat diseases of the central nervous system. Protein Delivery is located in Durham, NC | Health Technology |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Health Technology |
